| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q2 2018 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PHATHOM PHARMACEUTICALS INC | 16 | Q3 2023 | 69.8% |
| MERUS N V | 16 | Q3 2023 | 25.3% |
| VAXCYTE INC | 14 | Q3 2023 | 44.5% |
| OBSEVA SA | 12 | Q3 2022 | 5.7% |
| CENTESSA PHARMACEUTICALS PLC | 10 | Q3 2023 | 71.3% |
| AURA BIOSCIENCES INC | 8 | Q3 2023 | 22.9% |
| CHECKMATE PHARMACEUTICALS IN | 8 | Q2 2022 | 12.7% |
| NEWAMSTERDAM PHARMA COMPANY | 4 | Q3 2023 | 11.4% |
| SYNTHORX INC | 1 | Q4 2019 | 43.1% |
View Medicxi Ventures Management (Jersey) Ltd's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-15 |
| 13F-HR | 2024-02-01 |
| 3 | 2024-01-26 |
| 13F-HR | 2023-10-18 |
| 13F-HR | 2023-07-19 |
| 13F-HR | 2023-04-27 |
| 13F-HR | 2023-01-31 |
| 13F-HR | 2022-10-25 |
| 13F-HR/A | 2022-08-03 |
| 13F-HR | 2022-08-03 |
View Medicxi Ventures Management (Jersey) Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.